Company intelligence / Profile preview

Innovhem

Évry-Courcouronnes, Île-de-France, Franceinnovhem.fr ↗

Ownership: Private
Development stage: Preclinical

Overview

Innovhem has developed proprietary biomarkers and machine learning-based clinical algorithms to assess treatment efficacy and predict complications in sickle cell disease. Their single-cell HbF quantification technology is patented, with ongoing validation studies including participation in the HEMOPROVE Phase II trial. The company provides bioassays as a service to pharma/biotech partners for drug development support[1][3][4].

Therapeutic areas: Hematology
Modalities: BiomarkersClinical algorithms (AI/ML-based)Biological assays for fetal hemoglobin and intravascular hemolysis quantification[1][4]
Industry: Protein Biomarker Diagnostics

Partnerships

Academic partnerships with Inserm, APHP (Assistance Publique – Hôpitaux de Paris), UPEC, EFS; contract research collaborations with private companies[4].

Beyond the preview

Go deeper on Innovhem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovhem.

Explore the full profile